Welcome to LookChem.com Sign In|Join Free

HENAN SUNLAKE ENTERPRISE CORPORATION

Free supplier Enterprise Certification

Free
supplier
9th
years
Home>>Products>>Trilostane

Product Certification&
Enterprise Certification

More Detail

HENAN SUNLAKE ENTERPRISE CORPORATION

Country: China (Mainland)

Business Type:Trading Company

Ms.summer

Tel: +86-371- 86259723

Mr.William

Tel: 17734809689

Ms.lisa

Tel: 17734809689

Ms.Tina

Tel: 86-371-86259723

Ms.Ann

Tel: 17734809689

Ms.Helen

Tel: 17734809689

Mobile: 17734809689

Tel: +86-371- 86259723

Fax: +86-371- 86259723

Province/state: HENAN

City: ZHENGZHOU

Street: Mingmen International Center, NO.222 Dongming Road,Zhengzhou,Henan,China

MaxCard:


qq Contact Suppliers

Trilostane

CAS NO.13647-35-3

  • Min.Order: 1 Kilogram
  • Payment Terms: L/C,T/T
Contact Supplier

Product Details

Keywords

  • (2-alpha,4-alpha,5-alpha,17-beta)-4,5-epoxy-17-hydroxy-3-oxoandrostane-2-car
  • 17-beta)-ph
  • 4-alpha-5-epoxy-17-beta-hydroxy-3-oxo-5-alpha-androstane-2-alpha-carbonitril

Quick Details

  • ProName: Trilostane
  • CasNo: 13647-35-3
  • Molecular Formula: C20H27NO3
  • Appearance: White powder
  • Application: 13647-35-3
  • DeliveryTime: within 7-10days
  • PackAge: as required
  • Port: TIANJIN/SHANGHAI
  • ProductionCapacity: 100 Kilogram/Month
  • Purity: 99%
  • Storage: -20°C Freezer
  • Transportation: by air/ by sea/ by express
  • LimitNum: 1 Kilogram

Superiority

Trilostane Basic information
treatment of Cushing's syndrome Uses in dogs Indications Treatment history Mechanism The treatment of advanced breast cancer
Product Name: Trilostane
Synonyms: TRILOSTANE;(2-alpha,4-alpha,5-alpha,17-beta)-4,5-epoxy-17-hydroxy-3-oxoandrostane-2-car;17-beta)-ph;4-alpha,5-epoxy-17-beta-hydroxy-3-oxo-5-alpha-androstane-2-alpha-carbonitril;4-alpha,5-epoxy-3,17-dihydroxy-5-alpha-androst-2-ene-2-carbonitrile;4-alpha-5-epoxy-17-beta-hydroxy-3-oxo-5-alpha-androstane-2-alpha-carbonitril;androstane-2-carbonitrile,4,5-epoxy-17-hydroxy-3-oxo-,(2-alpha,4-alpha,5-al;modrenal
CAS: 13647-35-3
MF: C20H27NO3
MW: 329.43
EINECS: 237-133-0
Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals;Steroids;Inhibitor;FULVICIN
Mol File: 13647-35-3.mol
Trilostane Structure
 
Trilostane Chemical Properties
mp  264 °C
storage temp.  -20°C Freezer
CAS DataBase Reference 13647-35-3(CAS DataBase Reference)
EPA Substance Registry System Androst-2-ene-2- carbonitrile, 4,5-epoxy-3,17-dihydroxy-, (4.alpha.,5.alpha.,17.beta.)- (13647-35-3)
 
Safety Information
Hazard Codes  Xi
Risk Statements  36/37/38-62
Safety Statements  26-36/37
MSDS Information
Provider Language
Trilostane English
 
Trilostane Usage And Synthesis
treatment of Cushing's syndrome Trilostane is an inhibitor of 3β-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome and primary hyperaldosteronism. These are both disorders where excess amounts of corticosteroid hormones are produced in the body. Corticosteroids are essential for the body to make use of carbohydrates, fats and proteins and for a normal response to stress. They are also necessary for the regulation of salt and water balance in the body. Trilostane helps prevent the production of corticosteroids, controlling the symptoms associated with these disorders. 
Trilostane can also be useful in the treatment of breast cancer that has relapsed in women who have gone through menopause.
Uses in dogs Trilostane was withdrawn from the United States market in April 1994. However, it was approved in 2008 for the treatment of Cushing's disease (hyperandrenocorticism) in dogs.
It is also the first drug approved to treat both pituitary- and adrenal-dependent Cushing's in dogs.
1. has kidney or liver disease.
2. takes certain medications used to treat heart disease.
3. pregnant.
4. taking other medicines, including those available to buy without a prescription, herbal or complementary medicines.
5. had an allergic reaction to this or any other medicine.
Indications Trilostane can inhibit 3β-dehydrogenase in the synthesis of corticosteroids, and decrease the synthesis of cortisol and aldosterone. It also can be used in the treatment of Cushing's syndrome (hypercortisolism) and primary aldosteronism. But the efficacy to treat Cushing's syndrome (hypercortisolism) is not as metyrapone. This product also has a significant role in lowering blood testosterone levels, which may be related with that its synthesis is inhibited.
Treatment history Trilostane, that is 4α, 5α-epoxy-2-cyano-3,17β-diol, can reversibly inhibit 3β- hydroxy steroid dehydrogenase and △5, 4-isomerase in the adrenal cortex to block the biosynthesis of mineralocorticoid and glucocorticoid. In 1980, it was approved for the treatment of hyperaldosteronism and cortisol excess disease in the United Kingdom. In 1985, it was approved for the treatment of Cushing's syndrome in the United States, which is adrenal cortex hyperactivity disorder. In view of the older animals, especially older dogs are susceptible to Cushing's syndrome. Trilostane can relieve the disease symptoms of more than 90% of dogs, and improve their quality of life. So the drug has also been granted for the treatment of animals in the United Kingdom. Trilostane itself has no hormonal activity. Its side effects is less, and its safety and tolerability are also particularly good. 
The above information is edited by the chemicalbook of Ge Qian.
Mechanism Breast cancer is one of hormone-dependent tumors. And estrogen is the main driving factor of the growth of breast cancer cells. Thus, one of the modern treatment of breast cancer is the major target of estrogen through inhibiting the production of estrogen or block the action of estrogen or estrogen receptor in its site of action. It has been known that estrogen receptor is only a single receptor, but recent studies have identified that there are at least two subtypes α and β. Estrogen uniting with α- estrogen can stimulate cell growth, but it uniting with β-estrogen receptor can cut α- estrogen receptors and slow the rate of cell proliferation. Research revealed that the trilostane cannot only lower the production of estrogen, but also can modulate the binding of estrogen receptors on different subtypes. And meanwhile the dual effect of α-estrogen receptor inhibitors and β-estrogen receptor appears. Finally it can block and alter the negative effect of estrogen on cancer cells. The unique mode of action of trilostane can not only set it apart from other existing anti-estrogen drugs, but also be the pharmacological basis of that it is still highly effective on breast cancer in treatment failure with other anti-estrogen therapy or resistant breast cancer.
The treatment of advanced breast cancer Breast cancer is the most common type of tumor in women. Currently, for postmenopausal patients with hormone receptor-positive or unknown, clinical treatments unanimously recommend to be the preferred antiestrogen therapy, and the role of this therapy in delaying disease progression and improving survival time also has been affirmed and confirmed in numerous studies of breast cancer. 
Trilostane (trade name Modrenal) developed by the biotechnology company has already been on the market. It can be used for the treatment of postmenopausal women that hormone-selective cancer has spread outside the breast. The pharmaceutical uses two ways to slow down the disease progression. For hormone-sensitive breast cancer, estrogen promotes the growth of cancer cells by acting to the two receptors. Estrogen receptor α is cancer accelerator, and estrogen receptor β is the brake. Modrenal strengthens estrogen adsorption to the estrogen receptor β, and weakens the adsorption to estrogen receptor α. Meanwhile it also acts on another loci AP1in cell DNA to reduce cell proliferation.
Chemical Properties Tan Crystals
Usage An inhibitor of steroid biosynthesis. Used as an adrenocortical suppressant. Used in the treatment of breast cancer
Usage antifungal, inhibits mitosis in metaphase

 

Details

Product information

Trilostane is an inhibitor of 3β-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome and primary hyperaldosteronism. These are both disorders where excess amounts of corticosteroid hormones are produced in the body. Corticosteroids are essential for the body to make use of carbohydrates, fats and proteins and for a normal response to stress. They are also necessary for the regulation of salt and water balance in the body. Trilostane helps prevent the production of corticosteroids, controlling the symptoms associated with these disorders. 
Trilostane can also be useful in the treatment of breast cancer that has relapsed in women who have gone through menopause.

1)Basic information

treatment of Cushing's syndrome Uses in dogs Indications Treatment history Mechanism The treatment of advanced breast cancer
Product Name: Trilostane
Synonyms: TRILOSTANE;(2-alpha,4-alpha,5-alpha,17-beta)-4,5-epoxy-17-hydroxy-3-oxoandrostane-2-car;17-beta)-ph;4-alpha,5-epoxy-17-beta-hydroxy-3-oxo-5-alpha-androstane-2-alpha-carbonitril;4-alpha,5-epoxy-3,17-dihydroxy-5-alpha-androst-2-ene-2-carbonitrile;4-alpha-5-epoxy-17-beta-hydroxy-3-oxo-5-alpha-androstane-2-alpha-carbonitril;androstane-2-carbonitrile,4,5-epoxy-17-hydroxy-3-oxo-,(2-alpha,4-alpha,5-al;modrenal
CAS: 13647-35-3
MF: C20H27NO3
MW: 329.43
EINECS: 237-133-0
Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals;Steroids;Inhibitor;FULVICIN
Mol File: 13647-35-3.mol
Trilostane Structure
2)Chemical Properties
mp  264 °C
storage temp.  -20°C Freezer
CAS DataBase Reference 13647-35-3(CAS DataBase Reference)
EPA Substance Registry System Androst-2-ene-2- carbonitrile, 4,5-epoxy-3,17-dihydroxy-, (4.alpha.,5.alpha.,17.beta.)- (13647-35-3)

3)Safety Information
Hazard Codes  Xi
Risk Statements  36/37/38-62
Safety Statements  26-36/37
Provider Language
Trilostane English

4)Trilostane Usage

Trilostane was withdrawn from the United States market in April 1994. However, it was approved in 2008 for the treatment of Cushing's disease (hyperandrenocorticism) in dogs.
It is also the first drug approved to treat both pituitary- and adrenal-dependent Cushing's in dogs.
1. has kidney or liver disease.
2. takes certain medications used to treat heart disease.
3. pregnant.
4. taking other medicines, including those available to buy without a prescription, herbal or complementary medicines.
5. had an allergic reaction to this or any other medicine.

Company information

 Henan sunlake enterprise corporation is located in Henan Province , The central plain of China , Which enjoys favorable geogeaphical position and convenient transportion, The com[any was established in june. 1998 , until now having more than 18 years experience in manufacturing & exporting chemical raw material .

     Sunlake is a professional manufacturer engaged in producing and selling chemicals,including Organic & inorganic chemicals , pigments & Dyestuffs ,  Water treatment chemicals , Food & FEED additives and others . these products have been being well exported to europe , southeast Asia , the Middle East ,  Africa , South America and some other countries and areas.

    We sincerely welcome foreign friends to visit our plant for cooperation. With the idea of "quality first,credit priority, Excellent service", We are highly acknowledged by customers for good quality and competitive price. More importantly , the company has a strong R & D team, who are professional engineers and scholars with Ph. D. .So we are confident to serve you  better with our high - quality products and professional team.

    We are taking great efforts to provide our customers with demanded goods and professional services, and continuously improve our core ability of competition and get the momentum for sustainable development, and finally make us being a reliable and professional wupplier in international market.

    We  welcome any serious inquiries from all customers of the world, and sincerely hope to cooperate.

 

 

Hot Product